Informations

Progress in First-Line Treatment of Advanced Gastric Cancer Targeted Therapy + Chemotherapy ± Immunotherapy: Advances and Breakthroughs CLDN18.2 The SPOTLIGHT and GLOW studies are global, multicenter, randomized, double-blind, placebo-controlled phase…

Editor’s Note: According to the latest data released by the National Cancer Center, over 350,000 new cases of gastric cancer are diagnosed annually in China, making it the fifth most…

Advances in Neoadjuvant Therapy Neoadjuvant therapy has become a critical strategy for locally advanced gastric cancer (LAGC), with increasing emphasis on the role of immunotherapy and targeted therapy. 1. Immunotherapy…

Defining BCR and Advancements in NHT Therapy Biochemical recurrence (BCR) in prostate cancer refers to a rise in PSA levels following radical treatment without evidence of imaging-detectable metastasis. BCR signifies…

Gastric cancer remains a significant threat to human health. While breakthroughs in chemotherapy, targeted therapy, and immunotherapy have brought hope to patients, radical surgery remains the cornerstone of gastric cancer management. Recent years have seen substantial advancements in surgical treatment, including the refinement of standard radical gastrectomy, the development of minimally invasive techniques such as…

At the European Society for Medical Oncology Asia Congress 2024 (ESMO Asia 2024), Dr. Danbo Wang from Liaoning Cancer Hospital presented the latest findings from the DUBHE-C-204 study during the Gynecological Oncology Oral Abstracts session (Abstract No. 373O). Oncology Frontier had the privilege of interviewing Professor Wang on-site to discuss the study’s key findings and…

Since the release of the CSCO Renal Cancer Diagnosis and Treatment Guidelines in 2013, the guidelines have undergone eight updates, significantly advancing the standardization of renal cancer management in China. Over the past year, significant progress has been made globally and domestically in renal cancer treatment, particularly in medical therapies that have influenced clinical practice.…

During the recent 2024 Straits Breast Cancer Forum and Fujian Medical Association Breast Disease Division Meeting, Oncology Frontier had the privilege of inviting Dr. Jian Huang from The Second Affiliated Hospital of Zhejiang University School of Medicine. He shared in-depth insights into advancements in neoadjuvant therapy for breast cancer downstaging and breast conservation, the significance…